Table 4.
LVMi model | LVH model | LAVi model | LAVi > 34 model | E/e′ model | E/e′> 14 model | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HR | p-value | FDR | HR | p-value | FDR | HR | p-value | FDR | HR | p-value | FDR | HR | p-value | FDR | HR | p-value | FDR | |
TRAILR2 | 1.59 | 0.004 | 0.21 | 1.65 | <0.001 | 0.033 | 1.62 | <0.001 | 0.046 | 1.65 | <0.001 | 0.025 | 1.63 | 0.002 | 0.077 | 1.61 | 0.002 | 0.089 |
CTSL1 | 2.99 | <0.001 | 0.007 | 3.52 | <0.001 | <0.001 | 3.40 | <0.001 | <0.001 | 3.73 | <0.001 | <0.001 | 3.20 | <0.001 | 0.002 | 3.18 | <0.001 | 0.001 |
Multivariable model included age, sex, body mass index, diabetes, systolic blood pressure, estimated glomerular filtration rate and rheumatoid arthritis duration plus echocardiographic parameters.
LVMi, left ventricular mass index; LVH, left ventricular hypertrophy; LAVi, left atrial volume index; TRAILR2, TNF-related apoptosis-inducing ligand receptor 2; CTSL1, Cathepsin L1.